Amnol Chimica Biologica S.r.l.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Amnol Chimica Biologica S.r.l. - overview
Established
1978
Location
Novara, -, Italy
Primary Industry
Pharmaceuticals
About
Based in Novara, Italy, and founded in 1978, AMNOL Biological Chemistry Srl operates as a provider and manufacturer of pharmaceuticals, such as health products for phlebology and lymphology. As of 2023, the company is led by its CEO, Giorgio Stefanelli. In May 2023, Ceres Pharma NV, a portfolio company of Naxicap Partners, acquired Amnol Chimica Biologica S. r.
l. The company is actively involved in conducting research and innovation in the field of biotechnology, resulting in the development of multiple patents in collaboration with renowned European pharmaceutical companies. Their product range encompasses health supplements, medical devices, and specialized equipment for phlebology, lymphology, and skin wellness. Additionally, the company offers health pills such as Lymphoguard, Lipolipase, Venovigor, and Wasotonal, which further contribute to their client's well-being.
Current Investors
Ceres Pharma NV
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.amnol.net
Verticals
Manufacturing
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Amnol Chimica Biologica S.r.l. - timeline of key events
Amnol Chimica Biologica S.r.l. - financials
| Fiscal Year Ended | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 5,062,528 | 5,153,527 | 5,247,044 | 5,116,220 | 5,155,749 | 5,220,845 | 5,408,914 | 5,257,961 | 6,211,109 | - | - | - |
| % Revenue Growth (YoY) | - | 1.8% | 1.8% | (2.5%) | 0.8% | 1.3% | 3.6% | (2.8%) | 18.1% | - | - | - |
| EBITDA (USD) | 278,122 | 606,017 | 696,074 | 891,197 | 589,354 | 639,248 | 1,017,115 | 1,038,441 | 1,519,458 | - | - | - |
| Operating Income (USD) | 197,914 | 537,808 | 635,351 | 826,698 | 528,069 | 583,891 | 974,452 | 959,456 | 1,442,084 | - | - | - |
| Operating Margin | 3.9% | 10.4% | 12.1% | 16.2% | 10.2% | 11.2% | 18.0% | 18.2% | 23.2% | - | - | - |
| % EBITDA Margin | 5.5% | 11.8% | 13.3% | 17.4% | 11.4% | 12.2% | 18.8% | 19.7% | 24.5% | - | - | - |
| NET Income (USD) | 29,912 | 261,232 | 437,852 | 555,742 | 415,613 | 398,062 | 681,720 | 663,824 | 1,019,899 | - | - | - |
| % Net Margin | 0.6% | 5.1% | 8.3% | 10.9% | 8.1% | 7.6% | 12.6% | 12.6% | 16.4% | - | - | - |
Amnol Chimica Biologica S.r.l. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | Amnol Chimica Biologica S.r.l. | - |
Displaying 1 - 1 of 1
Amnol Chimica Biologica S.r.l. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.